CDC probes hospitalizations after chikungunya vaccination

Five older adults have been hospitalized after receiving the chikungunya vaccine, Ixchiq, prompting the CDC to launch an investigation. 

Advertisement

The patients, all 65 or older, experienced cardiac or neurologic events, according to the agency’s website. In clinical trials, less than 10% of people vaccinated with Ixchiq had adverse reactions, including tenderness, headache, fatigue, myalgia, arthralgia, fever and nausea. 

The vaccine, approved in November 2023, is recommended for adults traveling somewhere with a chikungunya outbreak. Chikungunya is a mosquito-borne disease that causes fever and joint pain. Most patients recover after about a week, and it rarely results in death, according to the CDC.

The Advisory Committee on Immunization Practices will discuss the five hospitalizations at an upcoming meeting. The committee was scheduled to convene Feb. 26-28, but the meeting was postponed indefinitely.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Public Health

Advertisement

Comments are closed.